On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Lenvatinib, a well-established first-line treatment for advanced hepatocellular carcinoma, demonstrates the ability to reprogram the immunosuppressive tumour microenvironment into an immune-supportive ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.